---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-080576"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-07-13T23:59:59+00:00"
generated_at: "2026-06-13T08:35:12.826211+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eloxx reports ELX-02 Phase 2 data: partial remission in 1 of 3 Alport patients

## Summary
- Patient 4401-02 showed ~49% average reduction in UPCR (p=0.009) after 8 weeks of ELX-02.
- Two other patients (4401-01, 4402-01) had no meaningful change in proteinuria.
- All three patients had COL4A4 nonsense mutations and background RAAS blockade.
- Patient 4401-02's remission rebounded 1 month after treatment withdrawal.
- Results from KOL Day on June 27, 2023 disclosed via 8-K filed July 13.

## SEC filing metadata
- accession: 0001104659-23-080576
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923080576/0001104659-23-080576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923080576/tm2321215d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-080576
- JSON: https://secwatch.observer/filing/0001104659-23-080576.json
- Plain text: https://secwatch.observer/filing/0001104659-23-080576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.